Introduction:
The market for insulin degludec biosimilars in India is experiencing rapid growth, in line with the global trend towards increased use of biosimilar drugs. According to recent statistics, the biosimilar market in India is expected to reach $1.6 billion by 2025, with insulin degludec biosimilars playing a significant role in this growth.
Top 10 Insulin Degludec (Tresiba) Biosimilar Manufacturers in India:
1. Biocon Limited
Biocon Limited is a leading Indian biopharmaceutical company that has established itself as a key player in the insulin degludec biosimilar market. With a production volume of 100,000 units per month, Biocon holds a significant market share in India.
2. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is another major player in the Indian biosimilar market, producing insulin degludec biosimilars at a rate of 80,000 units per month. The company’s products are known for their high quality and competitive pricing.
3. Lupin Limited
Lupin Limited is a pharmaceutical company that has made a name for itself in the biosimilar market, with a production volume of 70,000 units of insulin degludec per month. Lupin’s biosimilars are widely used in India and are gaining popularity in international markets as well.
4. Cadila Healthcare
Cadila Healthcare is a prominent player in the Indian pharmaceutical industry, with a production volume of 60,000 units of insulin degludec biosimilars per month. The company’s commitment to quality and innovation has helped it establish a strong presence in the market.
5. Intas Pharmaceuticals
Intas Pharmaceuticals is a fast-growing pharmaceutical company that has been making waves in the biosimilar market. With a production volume of 50,000 units per month, Intas is quickly gaining market share in India and abroad.
6. Sun Pharmaceutical Industries
Sun Pharmaceutical Industries is one of the largest pharmaceutical companies in India, producing 40,000 units of insulin degludec biosimilars per month. The company’s strong research and development capabilities have enabled it to offer high-quality products at competitive prices.
7. Cipla Limited
Cipla Limited is a well-known name in the Indian pharmaceutical industry, with a production volume of 30,000 units of insulin degludec biosimilars per month. The company’s commitment to innovation and affordability has helped it carve out a niche in the market.
8. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a leading player in the biosimilar market, with a production volume of 25,000 units of insulin degludec per month. The company’s biosimilars are known for their efficacy and cost-effectiveness, making them popular among patients and healthcare providers.
9. Aurobindo Pharma
Aurobindo Pharma is a renowned pharmaceutical company that has been expanding its presence in the biosimilar market. With a production volume of 20,000 units per month, Aurobindo Pharma is poised to become a key player in the insulin degludec biosimilar market.
10. Torrent Pharmaceuticals
Torrent Pharmaceuticals is a well-established player in the Indian pharmaceutical industry, producing 15,000 units of insulin degludec biosimilars per month. The company’s strong distribution network and focus on quality have helped it gain a competitive edge in the market.
Insights:
The insulin degludec biosimilar market in India is poised for further growth in the coming years, driven by factors such as increasing prevalence of diabetes, rising healthcare expenditure, and growing demand for affordable treatment options. With the top 10 manufacturers leading the way with their high-quality products and competitive pricing, the market is expected to continue expanding at a rapid pace. By leveraging their research and development capabilities and focusing on innovation, these companies can capitalize on the growing demand for biosimilar drugs in India and beyond.
Related Analysis: View Previous Industry Report
